affirm tirzepatide Mounjaro patent expiration: Drug patents expiring in 2036 mounjaro patent expiration date tirzepatide

[1] In the pivotal SURMOUNT-1 clinical trial, musculoskeletal complaints such as back pain, arthralgia, and myalgia were reported but did not occur at significantly higher rates than in the placebo group

The weight loss one can achieve with Tirzepatide varies significantly based on individual circumstances, including the amount of weight to lose and any additional weight-related health concerns

When people stop taking the medication, their appetite typically returns, and they may regain weight

GLP-1 receptor agonists work by mimicking the action of naturally occurring GLP-1, a hormone that stimulates insulin secretion in response to food intake, suppresses glucagon release, slows gastric emptying, and promotes satiety

You may see things like rashes, itching, or trouble breathing